{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:37:19Z","timestamp":1791218239194,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.lpm.2014.07.011","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T14:45:53Z","timestamp":1408373153000},"page":"981-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Traitement de l\u2019hypertension art\u00e9rielle pulmonaire"],"prefix":"10.1016","volume":"43","author":[{"given":"Olivier","family":"Sitbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ja\u00efs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2014.07.011_bib0005","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrcardio.2011.104","article-title":"Treatment of pulmonary arterial hypertension with targeted therapies","volume":"8","author":"O\u2019Callaghan","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0272-5231(05)70288-4","article-title":"Medical therapy of pulmonary hypertension. Conventional therapies","volume":"22","author":"Naeije","year":"2001","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ccm.2013.09.002","article-title":"Lung transplantation and atrial septostomy in pulmonary arterial hypertension","volume":"34","author":"Norfolk","year":"2013","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0025","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Task Force for Diagnosis, Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC)","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0030","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0035","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0040","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1183\/09031936.00027909","article-title":"Effects of exercise training in patients with idiopathic pulmonary arterial hypertension","volume":"34","author":"De Man","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1183\/09031936.00123711","article-title":"Safety and efficacy of exercise training in various forms of pulmonary hypertension","volume":"40","author":"Gr\u00fcnig","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/00000542-200506000-00012","article-title":"Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15\u00a0consecutive cases","volume":"102","author":"Bonnin","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.lpm.2014.07.011_bib0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/eurheartj\/ehn597","article-title":"Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?","volume":"30","author":"B\u00e9dard","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00141211","article-title":"Pregnancy outcomes in pulmonary arterial hypertension in the modern management era","volume":"40","author":"Ja\u00efs","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0065","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1183\/09031936.00113009","article-title":"Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension","volume":"35","author":"Price","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0070","doi-asserted-by":"crossref","first-page":"R169","DOI":"10.1186\/cc9264","article-title":"Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review","volume":"14","author":"Price","year":"2010","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.lpm.2014.07.011_bib0075","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0095","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0100","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/pcad.2002.128449","article-title":"Primary pulmonary hypertension: current therapy","volume":"45","author":"Sitbon","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.lpm.2014.07.011_bib0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0115","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0120","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.healun.2008.11.913","article-title":"Low complication rates with totally implantable access port use in epoprostenol treatment of pulmonary hypertension","volume":"28","author":"Dickinson","year":"2009","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"key":"10.1016\/j.lpm.2014.07.011_bib0130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.mayocp.2012.05.014","article-title":"Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY\u00ae","volume":"87","author":"Kitterman","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.lpm.2014.07.011_bib0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ahj.2013.08.007","article-title":"EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension","volume":"167","author":"Sitbon","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0145","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"key":"10.1016\/j.lpm.2014.07.011_bib0155","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0165","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2014.07.011_bib0170","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2014.07.011_bib0175","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0180","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0185","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0190","unstructured":"Actelion's media release on June 16th, 2014. Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension."},{"key":"10.1016\/j.lpm.2014.07.011_bib0195","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.07.011_bib0200","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0205","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0210","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.07.011_bib0215","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1517\/14656566.2011.564159","article-title":"Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension","volume":"12","author":"O\u2019Callaghan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.lpm.2014.07.011_bib0220","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1164\/rccm.200404-445OC","article-title":"Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension","volume":"170","author":"Sitbon","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind, randomized placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/09031936.00117511","article-title":"Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension","volume":"41","author":"Savale","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0235","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0240","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0245","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0250","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0255","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/17425255.2013.804063","article-title":"Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment","volume":"9","author":"Chaumais","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0260","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0265","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0270","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0280","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Gali\u00e8","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0285","doi-asserted-by":"crossref","first-page":"D73","DOI":"10.1016\/j.jacc.2013.10.034","article-title":"Treatment goals of pulmonary hypertension","volume":"62","author":"McLaughlin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.07.011_bib0290","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0295","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0300","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.07.011_bib0305","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.healun.2012.08.004","article-title":"The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012","volume":"31","author":"Christie","year":"2012","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"key":"10.1016\/j.lpm.2014.07.011_bib0310","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201109-1599OC","article-title":"Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation","volume":"185","author":"Fuehner","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0315","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157488711796575504","article-title":"Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here?","volume":"6","author":"Macchia","year":"2011","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.lpm.2014.07.011_bib0320","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1183\/09031936.00092311","article-title":"The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension","volume":"39","author":"Nickel","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0330","unstructured":"Actelion's media release on March 17th, 2014. An update on the bosentan study - COMPASS-2."},{"key":"10.1016\/j.lpm.2014.07.011_bib0335","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0340","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.07.011_bib0345","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.07.011_bib0350","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sild\u00e9nafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214003650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214003650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T02:58:31Z","timestamp":1565751511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498214003650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0755498214003650"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2014.07.011","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de l\u2019hypertension art\u00e9rielle pulmonaire","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2014.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}